药明生物(02269.HK):Positive profit alert: Strong execution made the year
机构:招商证券
评级:BUY
目标价:64.2港币
Positive profit alert: Strong execution made the year
Company’s 2017 GAAP earnings beat consensus by 12-15% on strong revenue growth and margin expansion, which in turn reflected the strong franchise value in its integrated biologics enabling platform
We revised up 2017 adj NP by 3% but kept 18E/19E estimates unchanged, primarily on the currency headwind from the USD depreciation, as its USD-denominated backlog should continue to contribute the majority of revenue
That said, Company has started currency hedging; we remain convinced of mgmt.’s execution capabilities, and upgraded TP to HK$64.2 reflecting 1.5x PEG; reiterate BUY
Positive profit alert showed a strong beat on consensus
Company released a positive profit alert, confirming that its FY17 net profit could reach RMB247mn-RMB254mn, up 75%-80% YoY, on strong revenue growth and efficiency gains. Excluding the one-off forex conversion loss related to the IPO proceeds, we believe that the GAAP NP should represent some 12-15% beat on consensus GAAP NP. We further calculate that the non-GAAP net profit should be RMB400mn-410mn, representing a quite significant beat on consensus’s earnings and some 3-5% beat on our adjusted NP.
Our 2018/19E EPS unchanged on potential forex headwind
Despite the earnings beat in 17E, we refrained from upgrading 2018/19E EPS now, which mainly reflects our cautious stance on the operational effect from Forex. We estimate that if USD/RMB exchange rate stays where it is today for the rest of 2018, our 2018 revenue/EBIT estimates would be affected by c.-5%/-12%, other things being equal. That said, we understand that management has already started currency hedging to mitigate the risk.
TP revised up to HK$64.2
Meanwhile, Wuxi Bio’s delivery of strong financial results in 2017 made us more convinced of the quality in its biotech enabling platform. Our new TP is based on 1.5x PEG (from 1x before) with 2018-20E EPS CAGR of 70%. This is driven by 1) positive pipeline updates in several of its late stage customers from 2H17 (Amicus, Momenta, etc.); 2) the potentially easing HK listing rules that should allow many Chinese biotech firms to recapitalise and finance their pipelines, which could create opportunities for groups like Wuxi Bio.
- 公用事业要涨价?六部委为地方政府提供政策支持
- 电信运营商持续加大智算投资,算力需求持续增长,上游光器件供需或趋紧
- 钨系产品价格持续走高,我国在供应端具有主导权,券商看至18-20万元/吨
- 华为全力打造鸿蒙为全球第三大移动操作系统,下游伙伴主要有四类
- 国家级及地方性政策密集出台,低空经济腾飞基础设施先行
- 发改委推动所有增发国债项目6月底前开工建设,基建投资、设备更新需求有望加速释放
- 煤炭产能储备制度+供给端收缩预期+高分红属性,机构建议关注煤炭历史性配置机遇
- 银行一季度业绩为全年中相对低点,关注市场对红利品种的配置需求及三条递进主线
- 中高端机床市场需求旺盛,设备更新+海外需求向好双轮驱动
- 船舶出口额同比增超110%,机构称新一轮大周期已至船舶优质资产性价比凸显